Carmustine medac (previously Carmustine Obvius) Europska Unija - hrvatski - EMA (European Medicines Agency)

carmustine medac (previously carmustine obvius)

medac gesellschaft für klinische spezialpräparate mbh - кармустином - hodgkin disease; lymphoma, non-hodgkin - antineoplastična sredstva - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Karmustin Pliva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

karmustin pliva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - karmustin - prašak i otapalo za koncentrat za otopinu za infuziju - 100 mg - urbroj: jedna bočica praška sadrži 100 mg karmustina

Karmustin Teva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

karmustin teva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju

teva b.v., swensweg 5, haarlem, nizozemska - karmustin - prašak i otapalo za koncentrat za otopinu za infuziju - 100 mg - urbroj: jedna bočica praška sadrži 100 mg karmustina

Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau) Europska Unija - hrvatski - EMA (European Medicines Agency)

chenodeoxycholic acid leadiant (previously known as chenodeoxycholic acid sigma-tau)

leadiant gmbh - Хенодезоксихолевая kiselina - xanthomatosis, cerebrotendinous; metabolism, inborn errors - bile i jetrena terapija - chenodeoxycholic kiselina je indiciran za liječenje urođene pogreške primarne žučne kiseline sinteze zbog nedostatka sterol 27 hidroksilaze (predstavlja kao cerebrotendinous xanthomatosis (ctx)) u dojenčadi, djece i adolescenata u dobi od 1 mjeseca do 18 godina i odrasle osobe.

Erleada Europska Unija - hrvatski - EMA (European Medicines Agency)

erleada

janssen-cilag international nv - apalutamide - prostatske neoplazme - endokrinska terapija - erleada drugačije:kod odraslih muškaraca u liječenju ne metastatic кастраци-uporan je rak prostate (nmcrpc), koje imaju visok rizik za razvoj bolesti метастатической. kod odraslih muškaraca u liječenju метастатического hormonski-senzitivni rak prostate (mhspc) u kombinaciji s terapijom oduzimanja андрогена (adt).

Revolade Europska Unija - hrvatski - EMA (European Medicines Agency)

revolade

novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Mavenclad Europska Unija - hrvatski - EMA (European Medicines Agency)

mavenclad

merck europe b.v. - Кладрибин - multipla skleroza - imunosupresivi - liječenje odraslih pacijenata s visoko aktivnom recidivnom multiple sklerozom (ms) kao što je definirano kliničkim ili imaging značajkama.